Mechanistic Insights into Deoxynivalenol-Induced Liver Injury: Overactivation of Mitophagy and Inhibition of the p62-Keap1-Nrf2 Pathway

Study Background and Research Question

Deoxynivalenol (DON), a mycotoxin produced by Fusarium species, is a persistent contaminant in cereal grains and animal feed worldwide. Its chemical stability makes it nearly impossible to eliminate from food chains using standard processing, as highlighted by high contamination rates across continents—over 80% in East Asia and upwards of 95% in some food products in the United States and China, according to the reference study. DON is rapidly absorbed and accumulates in the liver, the central organ for xenobiotic detoxification, leading to concerns about its hepatotoxic potential. Despite previous associations between DON exposure and hepatic dysfunction, the precise molecular mechanisms driving DON-induced liver injury have remained incompletely understood.

Key Innovation from the Reference Study

The pivotal innovation of this study is the elucidation of a dual mechanism by which DON provokes hepatotoxicity. The authors demonstrate that DON not only overactivates PINK1/Parkin-mediated mitophagy—leading to excessive mitochondrial turnover and injury—but also suppresses the p62-Keap1-Nrf2 cytoprotective axis. This suppression undermines the antioxidant defense system, exacerbating oxidative stress and cellular damage. The integrative approach linking mitochondrial quality control with redox signaling provides a more comprehensive understanding of DON-induced liver injury than prior models, which often examined these pathways in isolation.

Methods and Experimental Design Insights

The investigation employed both in vivo (mouse) and in vitro (AML-12 murine hepatocyte) models. Mice were administered DON orally at 0–4.8 mg/kg daily for seven days, while AML-12 cells were exposed to 0–6.4 μM DON for 24 hours. The study leveraged pharmacological (Mdivi-1, a mitophagy inhibitor) and genetic (siRNA-mediated PINK1 knockdown) interventions to dissect the role of mitophagy. To interrogate the Nrf2 pathway, p62 overexpression vectors were employed, allowing the authors to assess the impact of restoring this axis on DON-induced injury.

• Hepatic histopathology and liver function markers provided evidence of organ injury.
• Mitochondrial integrity and mitophagy were measured by transmission electron microscopy, immunofluorescence for LC3 and PINK1/Parkin, and Western blotting for mitophagy-associated proteins.
• The activity of the p62-Keap1-Nrf2 pathway was monitored using immunoprecipitation, nuclear translocation assays, and quantification of downstream antioxidant genes.
• Oxidative stress, apoptosis, inflammation, and lipid metabolism were evaluated using established biochemical assays and qPCR.

Core Findings and Why They Matter

The authors found that DON exposure led to excessive activation of PINK1/Parkin-mediated mitophagy, resulting in mitochondrial damage and increased hepatocyte apoptosis. Importantly, pharmacological or genetic dampening of this pathway (via Mdivi-1 or si-PINK1) attenuated mitochondrial injury and cell death, corroborating the pathogenic role of excessive mitophagy. Simultaneously, DON suppressed the p62-Keap1-Nrf2 pathway, as evidenced by reduced p62 expression, impaired Nrf2 nuclear translocation, and decline in antioxidant gene expression. This suppression compromised the cell's ability to manage oxidative stress, further amplifying liver damage.

A notable mechanistic insight is that enforced overexpression of p62 restored Nrf2 activation and significantly alleviated DON-induced hepatotoxicity. This finding positions p62 as a potential intervention point for mitigating DON toxicity. The dual hit—mitochondrial dysfunction and compromised antioxidant defense—provides a compelling model for understanding DON-induced liver injury, with implications for both environmental toxicology and translational liver research. These mechanisms may also be relevant for other forms of hepatotoxin-induced injury where mitochondrial quality control and redox homeostasis intersect.

Comparison with Existing Internal Articles

Several internal resources discuss the strategic targeting of signaling pathways in liver injury and oncology models. For example, the article "Advancing Liver Injury Models: Anti-ROR1 Antibody (Zilovertamab)" examines how Wnt5a-induced ROR1 signaling inhibition can modulate pathological processes in hepatic and tumor microenvironments. While the current DON study focuses on mitophagy and Nrf2 suppression, both bodies of work underscore the importance of dissecting cell signaling networks in liver injury research. The application of highly specific antibodies—such as Anti-ROR1 Antibody (Zilovertamab)—in functional and translational assays parallels the methodological rigor employed in the DON study, especially regarding pathway specificity and validation using ELISA or FACS-based methods.

Other internal articles, such as "Anti-ROR1 Antibody (Zilovertamab): Specificity & Integration Guide", reinforce the need for validated reagents in mechanistic studies. While these articles center on oncology and Wnt/β-catenin signaling, the workflow recommendations—such as antibody validation, kinetic studies, and functional assays—are applicable to the complex pathway analyses demonstrated in the DON liver injury model.

Limitations and Transferability

Despite its strengths, the study has several limitations. First, while both in vivo and in vitro models were employed, all experiments were performed in mice or murine cell lines, which may not fully recapitulate human hepatic physiology. Second, the study focuses on a subacute exposure paradigm; chronic or lower-dose exposures could involve additional or alternative mechanisms. Third, while the p62-Keap1-Nrf2 axis was shown to be protective, the full spectrum of antioxidant and stress response pathways was not examined. Extrapolation to other mycotoxins or environmental hepatotoxins should be done cautiously, as pathway interactions may differ.

Furthermore, while the findings highlight the importance of mitochondrial quality control and redox signaling in DON-induced liver injury, translation to clinical or agricultural practice would require further validation in human cells and long-term exposure models. The mechanistic framework, however, is broadly transferable to studies examining the intersection of mitophagy, cell stress, and liver pathology.

Protocol Parameters

• DON exposure in mice: 0–4.8 mg/kg daily, administered orally for 7 days to induce subacute liver injury and evaluate hepatotoxic mechanisms.
• Cell culture DON treatment: 0–6.4 μM DON exposure for 24 hours in AML-12 hepatocyte cell lines for mechanistic pathway studies.
• Mitophagy inhibition: Mdivi-1 administration or PINK1 siRNA transfection prior to DON exposure in both models to distinguish the role of mitophagy in injury.
• Antioxidant pathway rescue: Transient p62 overexpression via plasmid transfection in cell models to test restoration of Nrf2 signaling and protective effects.
• Functional validation: Use of ELISA antibody panels and FACS antibody-based sorting to quantify apoptosis, oxidative stress markers, and pathway-specific proteins.

Research Support Resources

For researchers aiming to replicate or expand on this mechanistic framework—especially in the context of signaling specificity, functional assays, or pathway inhibition—validated reagents are essential. The Anti-ROR1 Antibody (Zilovertamab) (SKU F1460) is one such reagent, offering high specificity for Wnt5a-induced ROR1 signaling inhibition and robust performance in ELISA, FACS, and functional assays. Its characteristics—humanized monoclonal antibody targeting ROR1, high purity, and compatibility with diverse assay platforms—make it a valuable tool for translational studies investigating complex signaling pathways in liver injury or oncology models. For further insights into integrating such antibodies into liver or cancer research, see the detailed discussions in "Anti-ROR1 Antibody (Zilovertamab): Translational Insights and Assay Precision".